PubMed
Cagrilintide plus semaglutide for obesity: a randomized phase 2 trial
Frias et al., 2023
GLP-1 & MetabolicPhase 3S
CagriSema
Cagrilintide + Semaglutide
Investigational fixed-dose combination of cagrilintide and semaglutide.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 2
- Research grade
- S
- Community score
- 142
- Trackers
- 2,718
Trend index
Overview
About CagriSema
Investigational fixed-dose combination of cagrilintide and semaglutide.
- Category
- GLP-1 & Metabolic
- Regulatory status
- Phase 3
- Also known as
- Cagrilintide + Semaglutide
- Self-reports
- 21
Community
What 21 users report
21 community reports
Positive 2% · Neutral 3% · Negative 95%
Most reported benefits
Appetite
124
Most reported side effects
Digestive upset
41
Injection site irritation
40
Nausea
40
Dose distribution
Median: 2000+ mcg · Most common: 2000+ mcg
0–25
0
25–50
0
50–100
0
100–200
0
200–400
0
400–600
0
600–1000
0
1000–2000
2
2000+
122
Commonly stacked with
How repeat users are trending
Among repeat reporters, 84% said they felt similar to their last entry, 16% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 151 days · Based on 19 repeat reporters
Research
Cited research (1)
Source
Help
Frequently asked
What do PeptIQ users report about CagriSema?
This page summarizes 21 anonymized self-reports from PeptIQ users who track CagriSema, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
What research is cited for CagriSema?
1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is CagriSema safe to use?
This wiki does not assess safety or recommend use. CagriSema is listed as Phase 3. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of CagriSema?
Research, primarily in animal models, suggests CagriSema may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of CagriSema?
CagriSema is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified CagriSema as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of CagriSema?
The safety and effectiveness of CagriSema have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on CagriSema?
While there are over 200 published studies on CagriSema, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source